Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Thyroid Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Heterotaxy Syndrome 1Breast Neoplasms 1

Interventions

Cyclophosphamide 7fludarabine 4Dasatinib 2zimberelimab 1pembrolizumab 1palbociclib 1olaparib 1fluorodopa F 18 1Vincristine 1Vemurafenib 1Topotecan 1Temozolomide 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Magnetic Resonance Spectroscopy 1Influenza Vaccines 1Fluoxetine 1Fluorodeoxyglucose F18 1Everolimus 1Etoposide 1Doxorubicin 1Decitabine 1Cholestanetriol 26-Monooxygenase 1CVAD protocol 1Busulfan 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recurrence × Vemurafenib × Clear all
NCT01748149 2025-08-03

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

University of California, San Francisco

Phase EARLY_PHASE1 Completed
40 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡